# Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)

> **NCT02573493** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 96 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck
- Carcinoma, Squamous Cell of the Head and Neck
- Cancer of Head and Neck
- Cancer of the Head and Neck
- Head and Neck Cancer
- Neoplasms, Head and Neck

## Interventions

- **DRUG:** nab-Paclitaxel
- **DRUG:** Cisplatin
- **BIOLOGICAL:** Cetuximab
- **RADIATION:** Intensity-Modulated Radiation Therapy

## Key facts

- **NCT ID:** NCT02573493
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-13
- **Primary completion:** 2019-12-12
- **Final completion:** 2024-07-01
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2024-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02573493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02573493, "Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02573493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*